StockNews.com upgraded shares of TG Therapeutics (NASDAQ:TGTX – Free Report) from a sell rating to a hold rating in a research note released on Friday. Other equities research analysts have also issued reports about the company. The Goldman Sachs Group upgraded TG Therapeutics from a sell rating to a neutral rating and cut their price objective for the stock from $16.00 to $12.00 in a research report on Wednesday, August 2nd. HC Wainwright lifted their price objective on TG Therapeutics from $34.

https://www.dailypolitical.com/2023/08/12/tg-therapeutics-nasdaqtgtx-upgraded-to-hold-by-stocknews-com.html

#dailypolitical